Immatics announces ACTengine® IMA203 for advanced melanoma with a 54% response rate; plans Phase 3 trial by December 2024.
Immatics has released updated Phase 1b data for its ACTengine® IMA203, targeting PRAME in 28 patients with advanced melanoma. The treatment shows a confirmed objective response rate of 54%, with a median progression-free survival (PFS) of 6 months. The company plans to initiate a Phase 3 trial, "SUPRAME," by December 2024, enrolling 360 patients to assess median PFS as the primary endpoint for potential full approval.
October 10, 2024
6 Articles